A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

References

• Mohamedali A, Gäken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood. 2007;110(9):3365–3373.
   PubMed Web of Science ®Google Scholar
• Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10(3):272–281.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Shafrin J, Green S, Murphy R, et al. Quantifying the economic burden of myelodysplastic syndromes among elderly US patients. Blood. 2019;134(Supplement_1):2151–2151.
   Google Scholar
• Fenaux P, Adès L. How we treat lower-risk myelodysplastic syndromes. Blood 2013;121(21):4280–4286.
   PubMed Web of Science ®Google Scholar
• Leukemia and Lymphoma Society of Canada. Available from: https://www.bloodcancers.ca/i-have-blood-cancer/myelodysplastic-syndromes.
   Google Scholar
• Pfeilstöcker M, Tuechler H, Sanz G, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902–910.
   PubMed Web of Science ®Google Scholar
• Li Z, Tang D, Tang J, et al. PS1503 estimating life-year loss of lower-risk myelodysplastic syndromes in Europe. HemaSphere. 2019;3(S1):693.
   Google Scholar
• Silzle T, Blum S, Schuler E, et al. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients. Blood Cancer J. 2019;9(8):63.
   PubMedGoogle Scholar
• Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(4):475–488.
   PubMed Web of Science ®Google Scholar
• Ohba R, Furuyama K, Yoshida K, et al. Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS). Ann Hematol. 2013;92(1):1–9.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569–572.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Belachew A, Finke C, et al. CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. Leukemia. 2014;28(6):1370–1371.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–3510.
   PubMed Web of Science ®Google Scholar
• Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. Can Med Assoc J. 2005;173(5):489–495.
   PubMed Web of Science ®Google Scholar
• EuroQol Research Foundation. EQ-5D-3L User Guide. Available from: https://euroqol.org/publications/user-guides/.
   Google Scholar
• EuroQol Research Foundation. EQ-5D-5L User Guide. Available from: https://euroqol.org/publications/user-guides/.
   Google Scholar
• Greenland S, Rothman K, editors. Applications to stratified analysis methods. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
   Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available from: https://www.R-project.org/. 2019.
   Google Scholar
• Bürkner PC. Advanced Bayesian multilevel modeling with the R package brms. The R Journal. 2018;10(1):395–411.
   Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Available from: https://www.equator-network.org/reporting-guidelines/strobe/.
   Google Scholar
• Vandenbroucke JP, von Elm E, Altman DG, STROBE Initiative, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805–835.
   PubMed Web of Science ®Google Scholar
• Dinmohamed AG, Visser O, van Norden Y, et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in The Netherlands from 2001 to 2010. Eur J Cancer. 2014;50(5):1004–1012.
   PubMed Web of Science ®Google Scholar
• de Swart L, Reiniers C, Bagguley T, EUMDS Steering Committee, et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2018;103(1):69–79.
   PubMed Web of Science ®Google Scholar
• Al-Kali A, Zblewski D, Foran JM, et al. Outcome of myelodysplastic syndromes over time in the United States: a national cancer data base study from 2004–2013. Mayo Clin Proc. 2019;94(8):1467–1474.
   PubMed Web of Science ®Google Scholar
• Germing U, Strupp C, Giagounidis A, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. Leuk Res. 2012;36(6):727–734.
   PubMed Web of Science ®Google Scholar
• Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. JAMA. 1998;279(23):1877–1882.
   PubMed Web of Science ®Google Scholar
• Molton IR, Terrill AL. Overview of persistent pain in older adults. Am Psychol. 2014;69(2):197–207.
   PubMed Web of Science ®Google Scholar
• Domenichiello AF, Ramsden CE. The silent epidemic of chronic pain in older adults. Prog Neuropsychopharmacol Biol Psychiatry. 2019;93:284–290.
   PubMed Web of Science ®Google Scholar
• Brunner AM, Blonquist TM, Hobbs GS, et al. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017;1(23):2032–2040.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136(2):157–170.
   PubMed Web of Science ®Google Scholar